INTRODUCTION
Osteoarthritis is the most common adult joint disease, and is increasing in frequency and severity, with an estimated US prevalence of more than 25 million affected adults. Disease progression is associated with cartilage degradation, joint space narrowing (JSN), and bony changes including osteophytes, subchondral sclerosis, and bone marrow lesions. However, identification of patients at risk for either incident disease or disease progression remains a challenge, particularly since routine radiography is an insensitive measure of molecular changes that presage cartilage and bone abnormalities. Therefore, there is a need for the validation of biochemical and imaging biomarkers that identify patients at risk for progressive disease; identify molecular events that detect early disease; and act as clinical surrogates that could respond to candidate disease-modifying osteoarthritis drug (DMOAD) intervention [1 && ]. Various disease-modifying treatments have been studied for osteoarthritis and, to date, none has achieved US Food and Drug Administration (FDA) approval as DMOADs. At present, DMOAD development must demonstrate slowing of radiographic JSN that is 'clinically meaningful' -that is, will be associated with improvement in symptoms or function. Given the high cost and recent failed attempts at DMOAD development, a significant international effort is underway to identify prognostic biomarkers that identify patients at increased risk for progression.
PROGNOSTIC BIOMARKERS OF SYNTHESIS AND DEGRADATION
An important classification of biomarkers was proposed by the Osteoarthritis Biomarkers Network, a consortium of five sites designated by the National Institutes of Health (NIH) [2] . The six categories (captured in the acronym BIPEDS) proposed to facilitate the development of osteoarthritis biomarkers include: Burden of disease, Investigative, Prognostic, Efficacy of intervention, Diagnostic, and Safety. Of particular importance for DMOAD development are prognostic biomarkers, which predict progression and/or future incidence of osteoarthritis. Validation of prognostic biomarkers requires longitudinal studies that demonstrate an association with development of osteoarthritis documented by radiography, or osteoarthritis progression as defined by JSN or change in cartilage volume by MRI. Additional outcomes of importance, but which are typically secondary endpoints in current studies, would include other measures of MRI worsening (e.g. bone marrow lesions), symptoms documented by patient questionnaires [e.g. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Knee Injury and Osteoarthritis Outcome Score (KOOS)], and total joint replacement.
The validation of prognostic biomarkers is of particular importance for clinical trial design, since the rate of progression in a non-selected osteoarthritis population may be as low as 6-20% of patients over a study period of 24 months, and as many as 50% of patients show no progression at all based on JSN or change in Kellgren-Lawrence score, making it difficult to show differences between placebo and an active comparator [1 && ]. Using prognostic biomarkers to identify patients at high risk for progression, and to select this subset for clinical trials, could reduce the number of patients and also the length of time required to observe a DMOAD effect. A focus of this article will be to review potential prognostic biomarkers of osteoarthritis, with an emphasis on reports since 2011.
Recently, the Biomarkers Working Group, representing experts in the field of osteoarthritis biomarker research from both academia and industry, developed a consensus document under the auspices of the Osteoarthritis Research Society International (OARSI) US FDA initiative [3] . The comprehensive article summarizes definitions and classification systems for biomarkers, the current outcome measures used in osteoarthritis clinical trials, and the potential utility of biomarkers for DMOAD development. The authors also propose a research agenda for osteoarthritis-related biomarkers. One recommendation was to focus significant future efforts across studies on selected commercially available osteoarthritis-related biomarkers, including urinary C-terminal telopeptides of type II collagen (uCTX-II); serum cartilage oligomeric matrix protein (COMP); serum hyaluronan; serum and urine C1, 2C; serum and urine C2C; serum and urine Coll2-1 and Coll2-1NO2; serum CPII; serum Procollagen type II N-terminal propeptide (PIIANP); urine/serum NTX-1; urine/serum CTX-1; serum CS846; and serum matrix metalloproteinase 3 (MMP-3). This panel was suggested as a starting point in a field that will rapidly evolve.
As is apparent, the biomarkers chosen include markers of collagen synthesis and degradation indicative of cartilage breakdown, and markers of bone and synovium breakdown. Excellent reviews of these biomarkers have been published in the past
. Serum COMP, uCTX-II, and serum hyaluronan are elevated in populations of patients with hip or knee osteoarthritis, and are among the list of candidate prognostic markers [8] . A recent metaanalysis by Hoch et al. [9 && ] found that serum COMP is elevated in patients with knee osteoarthritis and is sensitive to osteoarthritis disease severity. The potential of COMP as a prognostic marker has been previously reported in patients with symptomatic knee osteoarthritis (SKOA) [10, 11] . Recently, Golightly et al. [12 & ] reported that higher baseline COMP and hyaluronic acid serum levels predicted
KEY POINTS
Osteoarthritis is a disease of the whole joint affecting cartilage, synovium, bone, ligament, and muscles, leading to deterioration or loss of joint function.
On the basis of US Food and Drug Administration (FDA) recommendations, a biomarker can be defined as that which is 'objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.'
Studies have identified many candidate molecular biomarkers from the various joint tissues, some involved in synthesis and degradation, whereas others are more inflammatory in nature.
The cause of osteoarthritis varies among individuals; therefore development of biomarkers will allow differentiation of phenotypes, prognoses and rates of disease progression within a heterogeneous knee osteoarthritis population, and ultimately may facilitate the development of disease-modifying osteoarthritis drugs (DMOADs).
incident JSN, and higher COMP levels predicted incident knee osteophytes. Led by Hunter, the Boston Osteoarthritis Knee Study group examined the relationship between knee MRI changes and a number of markers of cartilage turnover, including COMP [13] . They found a six-fold increase in the likelihood of cartilage loss for each unit increase in COMP, after adjustment for age, sex, and BMI. In contrast, in a study of 75 patients, Eckstein et al. [14 & ] found that none of the 16 molecular markers (including uCTX-II, uTIINE, sCOMP, sPIINP, etc.) investigated was associated with longitudinal MRI-based cartilage thinning in radiographic knee osteoarthritis.
The complexity of biomarkers as predictors of disease progression is further underscored by a study by Pelletier et al. [15] showing that higher baseline values of interleukin (IL)-6, C-reactive protein (CRP), and COMP predicted greater risk of cartilage loss in osteoarthritis. However, over time a reduction in MMP-1 and MMP-3 levels correlated best with reduction in cartilage volume loss [15] ] showed that mechanical stress (30-min walk) produced a change in serum concentrations of COMP that was associated with cartilage thickness changes on MRI. In this study, increases in COMP levels 3.5 and 5.5 h after activity were correlated with changes in cartilage thickness in the medial femur and tibia at 5-year follow-up. A newly established COMP fragment ELISA showed greater sensitivity than the commercial kit in detecting differences between osteoarthritis and control patients [18 & ]. In addition, serum COMP fragment levels were well correlated with radiographic severity in osteoarthritis patients and progression of surgically induced osteoarthritis in murine models.
Like COMP, uCTX-II is among the well studied osteoarthritis biomarkers. Early studies by Garnero et al. [19] showed that elevated uCTX-II levels, particularly if associated with low serum levels of PIIANP (a marker of collagen 2 synthesis), conferred relative risks of progression of 2.9 by radiography and 9.3 by arthroscopy. In the Rotterdam study [20] of 1235 osteoarthritis patients, radiographic progression (mean duration 6.6 years) in both knees and hips was significantly associated with high baseline uCTX-II concentration. Elevated levels of CTX-II have also been found to predict progression of JSN in hip osteoarthritis [21, 22] 
INFLAMMATORY PROGNOSTIC BIOMARKERS
Although numerous subsets of inflammatory biomarkers are under evaluation in osteoarthritis, we will describe three key groups (Table 1) [34] further demonstrated the importance of low-grade inflammation within osteoarthritis joints, reporting that synovial fluid uric acid strongly correlated with synovial fluid IL-18 and IL-1b in a cohort of patients with knee osteoarthritis. All three biomarkers associated with osteoarthritis severity as measured by radiograph and/or bone scintigraphy. Synovial fluid IL-18 was associated with radiographic progression at 3 years. The authors concluded that correlation of synovial fluid uric acid with IL-18 and IL-1b suggested activation by uric acid of inflammasomes, supporting the potential involvement of the innate immune system in osteoarthritis pathology and progression.
Emerging literature indicates that the local inflammation within osteoarthritis joint tissues described above can be reflected in serum biomarkers, suggesting that in subsets of osteoarthritis patients there is evidence for systemic inflammation. One of the earliest studies was by Fraenkel et al. [35] , who reported associations of IL-1b production with the presence of knee osteophytes as well as JSN in women; these women also had higher rates of knee osteoarthritis, but lower rates of hand osteoarthritis. More recently, using a proteomic approach, serum proteins such as MIP-1a, IL-1a, IL-2, IL-15, and MMP-7 were shown by Ling et al. [53] to differentiate early osteoarthritis from controls.
Our lab has demonstrated elevations of prostaglandin E2 (PGE2), IL-1 receptor antagonist (IL-1Ra), and MMP-9 in SKOA patients [36 & ]. Plasma PGE2 levels in SKOA patients studied at baseline were twofold higher than in healthy controls and associated with disease severity. Among the plasma proteins studied, IL-1Ra predicted radiographic severity (KL1/2 vs. KL3/4). Elevated plasma levels of MMP-9 and IL-1Ra predicted JSN at 24 months. Nemirovskiy et al. [44] also reported elevations of plasma PGE2 as well as the lipoxygenase product, 15-HETE, in SKOA patients.
Baker et al. [54 & ] recently examined the association of fasting plasma phospholipid n-6 and n-3 polyunsaturated fatty acids (PUFAs) with synovitis (as measured by synovial thickening on contrastenhanced knee MRI) and cartilage damage among 472 patients in the Multicenter Osteoarthritis Study (MOST), finding an inverse relation between total n-3 PUFAs and the specific n-3, docosahexaenoic acid with patellofemoral cartilage loss. A positive association was observed between plasma levels of the pro-inflammatory n-6 PUFA, arachidonic acid, and synovitis [54 & 
]. Cohen et al. [31
& ] reported that patients treated with an anti-IL-1R1 monoclonal antibody showed statistically insignificant but numerically greater improvements in pain; minimal, if any, clinical benefit was observed. Of note, reductions of highly sensitive C-reactive protein (CRP) (hsCRP) levels (1.9 vs. 0.7 mg/l; P < 0.001) in treated patients occurred within 2 weeks of therapy and were sustained through week 16 of follow-up (8 weeks after last injection).
Elevated circulating levels of IL-6 and TNF-a in knee osteoarthritis have been reported by Stannus et al. [39] in 172 patients assessed at baseline and approximately 3 years' follow-up. T1-weighted fatsuppressed MRI of the right knee was performed at baseline and follow-up to determine cartilage loss over 2.9 years in older adults. At baseline, quartiles of IL-6 and TNF-a were associated with increased prevalence of medial tibiofemoral JSN (OARSI grade 1). Longitudinally, baseline IL-6 predicted loss of both medial and lateral tibial cartilage volume, independently of TNF-a. Change in IL-6 was associated with increased loss of medial and lateral tibial cartilage volume; change in TNF-a was also negatively associated with change in medial cartilage volume. In a subsequent study of osteoarthritis pain, Stannus et al. [32 && ] also found that baseline hsCRP was positively associated with worsening in total knee pain, as well as change in the pain at night in bed and while sitting/lying, over 2.7 years. Baseline TNF-a and IL-6 were associated with change in pain while standing, and change in TNF-a was positively associated with worsening of total knee and pain while standing.
In contrast, Vlad et al. [40 & ] reported no association between markers of inflammation and osteoarthritis of the hands and knees in the community-based Framingham Offspring cohort. In 1998-2001 patients provided blood specimens that were tested for 17 markers of systemic inflammation; in 2002-2005 patients had radiographs of knees and hands. Analysis indicated no association between any marker and the presence of radiographic osteoarthritis in any joint. It is difficult to compare this community cohort to the other populations in which positive associations have been reported, particularly as those were typically studies of patients with symptomatic osteoarthritis. In addition, the radiographic assessment in the Framingham cohort was separated from the prior blood sampling by a range of 3-7 years.
In interesting novel studies, Robinson and associates used proteomic and transcriptomic analyses of synovial fluids and membranes from patients with osteoarthritis, and determined that expression and activation of complement are abnormally high in human osteoarthritis joints [45 && ]. Using mice genetically deficient in C5, C6, or CD59a, and pharmacological inhibitors of complement in wild-type mice, the authors showed that complement, and specifically the membrane attack complex (MAC), is critical to development of osteoarthritis. The authors provide evidence that MAC acts, in part, via the activation of chondrocytes and release of MMPs, including MMP-13. Recent work from this laboratory utilized MS and multiplex bead-based immunoassay to survey proteins present in synovial fluid and sera of patients with SKOA compared to patients with rheumatoid arthritis (RA), as well as to sera from healthy individuals [38 && ]. Multiplex cytokine analysis revealed increased inflammatory proteins in sera of osteoarthritis patients compared to controls, including IL-1b, IL-1Ra, IL-6, MCP-1, Monokine induced by interferon gamma (CXCL9) (MIG), Vascular endothelial growth factor (VEGF), and granulocyte-macrophage colony-stimulating factor (GM-CSF). The levels of these cytokines were higher in osteoarthritis synovial fluid than sera, consistent with their origin from joint tissues. In this regard, the abnormal production and 'leakage' of inflammatory proteins into sera are analogous to that observed for more conventional biomarkers of joint tissue synthesis and degradation. In addition, the authors found that a large proportion of the proteins present in osteoarthritis synovial fluid activated cultured macrophages via TLR4 to induce the production of an array of inflammatory cytokines. They suggest that proteins present in osteoarthritis synovial fluid may contribute to low-grade inflammation in osteoarthritis by functioning as damage-associated molecular pattern (DAMP), that is, ligands of TLR4.
A recent study by Rübenhagen et al. [42 & ] demonstrated increased IL-7 levels in synovial fluid of osteoarthritis patients. IL-7 is a cytokine produced by osteoarthritis chondrocytes (among other cell types; IL-7-stimulated chondrocytes respond with proteoglycan release from cartilage [55] ). The authors also observed that MMP-1 levels decrease with radiographic severity of osteoarthritis, attributed to progressive loss of cartilage, the presumptive origin of the MMP production. Other cytokines, including IL-1Ra, were highly correlated with synovial levels of MMP-9, MIP-1a, and IL-8 [42 & ]. The findings that osteoarthritis is characterized by both local and systemic inflammatory conditions have been similarly observed in Inbred strain of mice (STR/ort) mice, a model for spontaneous osteoarthritis [43 && ]. Serum analysis showed higher concentrations of IL1b, IL12p70, MIP1b, and IL5, correlated with worsened joint morphology and local expression of inflammatory mediators.
Obesity-related inflammatory biomarkers
Obesity is one of the primary risk factors for developing both knee and hand osteoarthritis [56] . It is postulated that in addition to the biomechanical impact of obesity, which would not account for the increased incidence of hand osteoarthritis, some pro-inflammatory adipokines produced by adipose tissue contribute to development and progression of osteoarthritis [57] . Leptin, resistin, and adiponectin may contribute to obesity-associated osteoarthritis via actions on cartilage metabolism. A detailed review of the mechanism by which obesity contributes to osteoarthritis is provided by Berenbaum in this issue.
Koskinen et al. [46 && ] investigated adiponectin as a plasma biomarker in male osteoarthritis patients undergoing total knee replacement surgery. Plasma adiponectin levels were higher in patients with more radiologically severe osteoarthritis, and positively correlated with plasma levels of COMP and
] demonstrated the beneficial effect of bariatric surgery on knee osteoarthritis symptoms and systemic inflammatory biomarkers. Preoperatively, serum IL-6 levels were elevated and correlated with levels of hsCRP. Six months after surgery, knee pain decreased, as did serum levels of IL-6, hsCRP, COMP, and fibrinogen, whereas levels of N-terminal pro-peptide of type IIA collagen levels (a biomarker of cartilage synthesis) increased. Our group examined the effects of bariatric surgery on osteoarthritis symptoms, and similarly demonstrated significant decreases in knee pain [41] .
Transcriptomic biomarkers
We have recently reported that increased IL-1b gene expression in peripheral blood leukocytes (PBLs) is associated with increased pain and predicts risk for progression of SKOA [37 && ]. Inflammatory gene expression in PBL was assessed using microarray and further validated using qPCR. Radiographic progression at 2 years was assessed in 86 patients. Patients with the inflammatory 'IL-1b PBL signature' had higher pain scores, decreased function, and higher risk of radiographic progression. Since that publication additional patients have completed the 24-month study [36 & ], in whom PBL mRNA overexpression of IL-1b, TNF-a, and COX-2 at baseline predicted higher risk for radiographic progression, as measured by change in minimal medial joint space width. Similar observations have been made in a dog model of spontaneous osteoarthritis: inflammatory response genes, including TNF-a, were differentially expressed in PBLs (determined by microarray) [58 These data indicate that, in subsets of osteoarthritis patients at higher risk for radiographic progression, PBLs are activated by repeated circulation through diseased synovium and subchondral bone of affected joints. An alternative explanation was suggested by Hirohata et al. [59] , who demonstrated enhanced expression of mRNA for IL-6 and TNF-a by CD34þ hematopoietic precursor cells in bone marrow of both osteoarthritis and RA patients compared with normal individuals. This raises the intriguing possibility that activated peripheral mononuclear cells originate from a pool of activated precursor cells in the bone marrow of osteoarthritis joints. The above studies suggest that inflammatory biomarkers may identify subgroups among osteoarthritis patients in whom disease progresses at different rates. This may facilitate our understanding of osteoarthritis pathogenesis and allow us to differentiate disease phenotypes within a heterogeneous knee osteoarthritis population.
CONCLUSION
During the past decade, there have been significant developments in the scientific understanding of osteoarthritis. Aided by advances in imaging technology, we have come to appreciate that osteoarthritis is a disease of the 'whole joint' involving a complex series of molecular changes at the cell, matrix, and tissue levels, and complex interactions between the tissues that make up the joint. We are beginning to understand better the mechanisms by which genetic, mechanical, and metabolic risk factors initiate and perpetuate the biochemical changes that lead to progressive failure of the joint. However, DMOAD drug development has been hampered by the absence of validated and qualified biomarkers, particularly those that may predict disease incidence or progression. As described in this review, extensive work over the past decade has identified a significant number of candidate biomarkers that can now be focused upon in well characterized population studies and clinical trials. There is little doubt, given international effort in this area and a common focus on high-value candidate biomarkers, that the next several years will see major breakthroughs that may lead to effective therapies to reduce the symptoms and slow the progression of osteoarthritis. In patients treated with intra-articular injections of an antibody to the IL-1R1 receptor there were reductions of highly sensitive CRP (hsCRP) levels within 2 weeks of therapy, which were sustained for 8 weeks after the last injection. 32. 
